Persistence of Clinically Significant Portal Hypertension After Eradication of Hepatitis C Virus in Patients With Advanced Cirrhosis

Clin Infect Dis. 2020 Dec 17;71(10):2726-2729. doi: 10.1093/cid/ciaa502.

Abstract

This prospective study of 34 patients with HCV cirrhosis (17 HIV positive) with baseline clinically significant portal hypertension (CSPH; HVPG ≥10 mmHg) and SVR after DAA therapy showed that disappearance of CSPH (primary endpoint) is a rare event (6/18 patients; 18%), indicating a persistent risk of clinical progression or death.

Keywords: HCV; cirrhosis; direct-acting antiviral agents; eradication; portal hypertension.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / therapeutic use
  • Hepacivirus
  • Hepatitis C* / complications
  • Hepatitis C* / drug therapy
  • Hepatitis C, Chronic* / complications
  • Hepatitis C, Chronic* / drug therapy
  • Humans
  • Hypertension, Portal* / complications
  • Hypertension, Portal* / drug therapy
  • Liver Cirrhosis / complications
  • Liver Cirrhosis / drug therapy
  • Prospective Studies

Substances

  • Antiviral Agents